Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy?
Celcuity Inc. has appointed Charles (Chip) R. Romp, a seasoned oncology pharmaceutical executive, to its Board of Directors. This addition brings significant commercial and sales leadership experience, aligning with Celcuity’s goal of bringing targeted cancer therapies to market. While Romp’s expertise enhances launch planning and market access strategies, the company’s investment narrative still heavily relies on FDA review outcomes and clinical trial results, underscoring the binary nature of these upcoming catalysts.